跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
fluticasone propionate + salmeterol xinafoate
首页
药物
fluticasone propionate + salmeterol xinafoate
fluticasone propionate + salmeterol xinafoate
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
申请人: HANMI PHARM IND CO LTD
优先权: 2012
CN
US
4 件公开
NEW THERAPEUTIC INHALATION SYSTEM PROVIDING REDUCED DOSE OF FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE WITH IMPROVED EFFICACY AND SAFETY PROFILE
申请人: PRZED FARMACEUTYCZNE LEK AM SP Z O O
优先权: 2019
EP
Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
申请人: GLAXO GROUP LTD
优先权: 2012
US
Dry powder inhaler
申请人: TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC
优先权: 2015
CN
US
2 件公开
Dry powder inhaler
申请人: TEVA BRANDED PHARMACEUTICAL PROD R & D INC
优先权: 2014
US
2 件公开
Crystal structure
申请人: GLAXO WELLCOME INC
优先权: 1999
US
Inhalable pharmaceutical compositions and the inhaler devices containing them
申请人: SANOFI SA
优先权: 2014
CN
Pharmaceutical composition
申请人: MEXICHEM FLUOR SA DE CV
优先权: 2022
US
药物
反馈
